Business Context and Reporting Period
This Form 8-K Current Report is filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) for the period ending August 29, 2013, reporting events occurring on August 25, 2013. The filing addresses the termination of a material definitive agreement regarding the anti-cancer compound RX-3117.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a corporate event rather than financial performance data.
Material Changes
- Termination of Agreement: The Research and Exclusive License Option Agreement (RELO Agreement) with Teva Pharmaceutical Industries Limited terminated on August 25, 2013.
- Reason for Termination: Teva elected not to exercise its option to exclusively license RX-3117, citing a misalignment with its new oncology strategy following the submission of an Investigational New Drug (IND) application on July 10, 2013.
- Financial Impact: The termination occurred without a penalty to either party.
- Asset Transfer: Teva will transfer the IND for RX-3117 back to Rexahn, allowing Rexahn to retain all global development and commercialization rights.
Outlook and Management Commentary
Management announced via press release on August 28, 2013, that Rexahn will continue to advance the clinical development of RX-3117 independently. The company expects to finalize the timeline for initiating a Phase I clinical study in cancer patients within the next three months.
Investor Verification Checklist
- Verify the status of the IND application for RX-3117 now held by Rexahn.
- Confirm the revised timeline for the Phase I clinical study initiation.
- Assess Rexahn's internal resources and capital requirements to fund the global development of RX-3117 without Teva's partnership.
- Review the attached press release (Exhibit 99.1) for additional strategic details.